Inhibition of macrophage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells

BMC Cancer

Volumn 4, Issue , 2004, Pages

  Meyer Siegler, Katherine L ^a,b   Leifheit, Erica C ^a,c   Vera, Pedro L ^a,b  

^a Bay Pines VA Medical Center   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c ECKERD COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CD74 ANTIGEN; CYTOKINE ANTIBODY; CYTOKINE RECEPTOR; HERMES ANTIGEN; HYALURONIC ACID; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 289; UNCLASSIFIED DRUG; CD79 ANTIGEN; CD79A PROTEIN, HUMAN; CYTOKINE; INTERLEUKIN 1; LEUKOCYTE ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLADDER CANCER; CANCER CELL; CELL GROWTH; CELL PROLIFERATION; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NUCLEIC ACID PROBE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; WESTERN BLOTTING; BIOSYNTHESIS; BLADDER; BLADDER TUMOR; CELL DIVISION; CHEMISTRY; DOSE RESPONSE; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; SECRETION (PROCESS); TUMOR CELL CULTURE;

ANTIGENS, CD; ANTIGENS, CD44; ANTIGENS, CD79; CELL DIVISION; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYALURONIC ACID; INTERLEUKIN-1; MACROPHAGE MIGRATION-INHIBITORY FACTORS; RECEPTORS, ANTIGEN, B-CELL; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 13144292427     PISSN: 14712407     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2407-4-34     Document Type: Article

References (51)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ: Cancer statistics. CA Cancer J Clin 2003, 53:5-26.
2. Small EJ, Halabi S, Dalbagni G, Pruthi R, Phillips G, Edelman M, Bajorin D, Cancer and Leukemia Group B: Overview of bladder cancer trials in the cancer and leukemia group B. Cancer 2003, 97: 090-2098.
3. Piazza GA, Thompson WJ, Pamukeu R, Alila HW, Whitehead CM, Liu L, Fetter JR, Gresh WE Jr, Klein-Szanto AJ, Farnell DR, Eto I, Grubbs CJ: Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res 2001, 61:3961-3968.
4. Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF Jr: Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol 1989, 141:22-29.
5. La Vecchia C, Negri E, D'Avanzo B, Savoldelli R, Francesci S: Genital and urinary tract disease and bladder cancer. Cancer Res 1991, 51:629-631.
6. Vera PL, Meyer-Siegler KL: Anatomical location of macrophage migration inhibitory factor in urogenital tissues, peripheral ganglia and lumbosacral spinal cord of the rat. BMC Neuroscience 2003, 4:17.
7. Vera PL, Ordorica RC, Meyer-Siegler KL: Hydrochloric acid-induced changes in macrophage migration inhibitory factor in the bladder, peripheral and central nervous system of the rat. J Urol 2003, 170:623-627.
8. Meyer-Siegler KL, Ordorica RC, Vera PL: Macrophage migration inhibitory factor is upregulated in an endotoxin-induced model of bladder inflammation in rats. J Interferon and Cytokine Res 2004, 24:55-63.
9. Swope MD, Lolis E: Macrophage migration inhibitory factor: cytokine, hormone or enzyme? Rev Physiol Biochem Pharmacol 1999, 139:1-32.
10. Baugh JA, Bucala R: Macrophage migration inhibitory factor. Crit Care Med 2002, 30:S27-S35.
11. Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, Manogue KR, Cerami A, Bucala R: MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 1993, 365:756-759.
12. Leech M, Metz C, Hall P, Hutchinson P, Gianis K, Smith M, Weedon H, Holdsworth SR, Bucala R, Morand EF: Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis & Rheumatism 1999, 42:1601-1608.
13. de Jong YP, Abadia-Molina AC, Satoskar AR, Clarke K, Rietdijk ST, Faubion WA, Mizoguchi E, Metz CN, Alsahli M, ten Hove T, Keates AC, Lubetsky JB, Farrell RJ, Michetti P, van Deventer SJ, Lolis E, David JR, Bhan AK, Terhorst C, Sahli MA: Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol 2001, 2: 061-1066.
14. Kamimura A, Kamachi M, Nishihira J, Ogura S, Isobe H, Dosaka-Akita H, Ogata A, Shindoh M, Ohbuchi T, Kawakami Y: Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer 2000, 89:334-341.
15. Bando H, Matsumoto G, Bando M, Muta M, Ogawa T, Funata N, Nishihira J, Koike M, Toi M: Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread. Jpn J Cancer Res 2002, 93:389-396.
16. Meyer-Siegler K, Hudson PB: Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology 1996, 48:448-452.
17. Meyer-Siegler KL, Bellino MA, Tannenbaum M: Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer 2002, 94:1449-1456.
18. Nishihira J, Ishibashi T, Fukushima T, Sun B, Sato Y, Todo S: Macrophage migration inhibitory factor (MIF): Its potential role in tumor growth and tumor-associated angiogenesis. Ann NY Acad Sci 2003, 995:171-182.
19. Chesney J, Metz C, Bacher M, Peng T, Meinhardt A, Bucala R: An essential role for macrophage migration inhibitory factor in angiogenesis and the growth of a murine lymphoma. Molecul Med 1999, 5:181-191.
20. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, Delohery T, Chen Y, Mitchell RA, Bucala R: MIF Signal Transduction initiated by binding to CD74. J Exp Med 2003, 197:1467-1476.
21. Wraight C, vanEndert P, Moller P, Lipp J, Ling N, MacLennan CKN, Moldenhauer G: Human major histocompatibility class II invariant chain is expressed on the cell surface. J Biol Chem 1990, 265:5787-5792.
22. Naujokas MF, Morin M, Anderson MS, Peterson M, Miller J: The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell 1993, 74:257-268.
23. Naujokas MF, Arneson LS, Fineschi B, Peterson ME, Sitterding S, Hammond AT, Reilly C, Lo D, Miller J: Potent effects of low levels of MHC class II-associated invariant chain on CD4+ T cell development. Immunity 1995, 3:359-372.
24. Cichy J, Bals R, Potempa J, Mani A, Pure E: Proteinase-mediated release of epithelial cell associated CD44. J Biol Chem 2002, 277:44440-44447.
25. Okamoto I, Tsuiki H, Kenyon LC, Godwin AK, Emlet DR, Holgado-Madruga M, Lanham IS, Joynes CJ, Vo KT, Guha A, Matsumoto M, Ushio Y, Saya H, Wong AJ: Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathology 2002, 160: 41-447.
26. van der Gaag R, Broersma L, Koornneef L: The influence of high molecular weight sodium hyaluronate (Healon) on the production of migration inhibitory factor. Curr Eye Res 1987, 6: 433-1440.
27. Meyer-Siegler K, Fattor RA, Hudson PB: Expression of macrophage migration inhibitory factor in the human prostate. Diag Mol Path 1998, 7:44-50.
28. Seydel KB, Ellen LI, Swanson PE, Stanely SL Jr: Human intestinal epithelial cells produce proinflammatory cytokines in response to infection in a SCID mouse-human intestinal xenograft model of amebiasis. Infect Immun 1997, 65:1631-1639.
29. Lokeshwar VB, Young MJ, Goudarzi G, Iida N, Yudin AI, Cherr GN, Selzer MG: Identification of bladder tumor-derived hyaluronidase: Its similarity to HYAL1. Cancer Res 1999, 59:4464-4470.
30. Meyer-Siegler K: Cox-2 specific inhibitor, NS-398, increases macrophage migration inhibitory factor expression and induced neuroendocrine differentiation in C4-2b prostate cancer cells. Molecular Medicine 2001, 7:850-860.
31. Mitchell RA, Bucala R: Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Semin Cancer Biol 2000, 10:359-66.
32. Bini L, Magi B, Marzocchi B, Arcuri F, Tripodi S, Cintorino M, Sanchez JC, Frutiger S, Hughes G, Pallini V, Hochstrasser DF, Tosi P: Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis 1997, 18: 832-2841.
33. White ES, Flaherty KR, Carskadon S, Brant A, Iannettoni MD, Yee J, Orringer MB, Arenberg DA: Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res 2003, 9: 53-860.
34. Takahashi N, Nishihira J, Sato Y, Kondo M, Ogawa H, Ohshima T, Une Y, Todo S: Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth. Mol Med 1998, 4:707-714.
35. Akbar SM, Abe M, Murakami H, Tanimoto K, Kumagi T, Yamashita Y, Michitaka K, Horiike N, Onji M: Macrophage migration inhibitory factor in hepatocellular carcinoma and liver cirrhosis; relevance to pathogenesis. Cancer Lett 2001, 171:125-132.
36. Ren Y, Tsui HT, Poon RT, Ng IO, Li Z, Chen Y, Jiang G, Lau C, Yu WC, Bacher M, Fan ST: Macrophage migration inhibitory factor: Roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer 2003, 107:22-29.
37. Bacher M, Schrader J, Thompson N, Kuschela K, Gemsa D, Waeber G, Schlegel T: Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme. Am J Pathol 2003, 162:11-17.
38. Sasaki Y, Kasuya K, Nishihira J, Magami Y, Tsuchida A, Aoki T, Koyanagi Y: Suppression of tumor growth through introduction of an antisense plasmid of macrophage migration inhibitory factor. Int J Mol Med 2002, 10:579-583.
39. Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH: A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 1999, 190:1375-1382.
40. Ohkawara T, Nishihira J, Takeda H, Hige S, Kato M, Sugiyama T, Iwanaga T, Nakamura H, Mizue Y, Asaka M: Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice. Gastroenterology 2002, 123: 56-70.
41. Lolis E, Bucala R: Macrophage migration inhibitory factor. Expert Opin Ther Targets 2003, 7:153-164.
42. Murakami H, Akbar SM, Matsui H, Horiike N, Onji M: Macrophage migration inhibitory factor activates antigen-presenting dendritic cells and induces inflammatory cytokines in ulcerative colitis. Clin Exp Immunol 2002, 128:504-510.
43. Matza D, Kerem A, Shachar I: Invariant chain, a chain of command. Trends in Immunology 2003, 24:264-268.
44. Calandra T, Bernhagen J, Mitchell RA, Bucala R: The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994, 179: 895-1902.
45. Stavitsky AB, Xianli J: In vitro and in vivo regulation by macrophage migration inhibitory factor (MIF) of expression of MHC-II, costimulatory, adhesion, receptor, and cytokine molecules. Cellular Immunol 2002, 217:95-104.
46. Matza D, Wolstein O, Dikstein R, Shachar I: Invariant chain induces B cell maturation by activating TAFII105-NF-κβ dependent transcription program. J Biol Chem 2001, 276:27203-27206.
47. Cichy J, Pure E: The liberation of CD44. J Cell Biol 2003, 161:839-843.
48. Sugahara KN, Murai T, Nishinakamura H, Kawashima H, Saya H, Miyasaka M: Hyaluronan oligosaccharides induce CD44 cleavage and promote cell migration in CD44-expressing tumor cells. J Biol Chem 2003, 278:32259-32265.
49. Okamoto I, Kawano Y, Murakami D, Sasayama T, Araki N, Miki T, Wong AJ, Saya H: Proteolytic release of CD44 intracellular domain and its role in CD44 signaling pathway. J Cell Biol 2001, 155: 55-762.
50. Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, Gutmann DH, Ponta H, Herrlich P: The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 2001, 15:968-980.
51. Mitchell RA, Metz CN, Peng T, Bucala R: Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem 1999, 274:18100-18106.